机构:[1]Department of Oncology,First Affiliated Hospital, Guangzhou University of Chinese Medicine[2]Department of Preventive Medicine and Biostatistics ,School of Basic Medical Science, Guangzhou University of Chinese Medicine[3]Department of Oncology,Guangzhou Hospital of Traditional Chinese Medicine, Guangzhou, Guangdong, China
Context. Shuangbai San is a Chinese herb preparation used externally to treat pain. There have been few randomized controlled trials addressing the safety and usefulness of Shuangbai San, such as its effect on pain relief and quality of life (QOL) improvement. Objectives. This study was conducted to evaluate the effect of Shuangbai San on relieving pain and improving QOL in primary liver cancer patients with cancer pain. Methods. A total of 134 primary liver cancer patients with mild pain (numerical rating scale [NRS] #3), either locally in the liver or in the upper abdomen, were enrolled and randomly allocated to the group receiving Shuangbai San or the control group (receiving placebo). The primary outcome measures were the NRS score and QOL scales, including the QOL scale for patients with liver cancer, version 2.0 and the European Organization for Research and Treatment of Cancer QOL Questionnaire-C30. The secondary outcome measures included the Karnofsky Performance Status score, blood indicators, and liver and kidney function before and after treatment. Results. The NRS scores decreased more significantly in the Shuangbai San group than in the placebo group (P < 0.05) at the corresponding time points. The changes in the scores for the physical function, psychological function, and symptoms/adverse effects domains of the QOL scale for patients with liver cancer, version 2.0 and the physical, emotional, and cognitive domains of the European Organization for Research and Treatment of Cancer QOL Questionnaire-C30 were significantly greater in the Shuangbai San group than in the placebo group (P < 0.05). The changes in the scores for the other domains were not significantly different (P > 0.05). Conclusion. The use of Shuangbai San can relieve mild pain in liver cancer patients and improve their QOL. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
基金:
"Eleventh Five-Year'' National Technology Support Program of China [2008BAI53B022]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类|3 区医学
小类|3 区临床神经病学3 区卫生保健与服务3 区医学:内科
最新[2025]版:
大类|2 区医学
小类|2 区临床神经病学2 区卫生保健与服务2 区医学:内科
JCR分区:
出版当年[2014]版:
Q1HEALTH CARE SCIENCES & SERVICESQ1MEDICINE, GENERAL & INTERNALQ2CLINICAL NEUROLOGY
最新[2023]版:
Q1HEALTH CARE SCIENCES & SERVICESQ1MEDICINE, GENERAL & INTERNALQ2CLINICAL NEUROLOGY
第一作者机构:[1]Department of Oncology,First Affiliated Hospital, Guangzhou University of Chinese Medicine
通讯作者:
通讯机构:[1]Department of Oncology,First Affiliated Hospital, Guangzhou University of Chinese Medicine[*1]Department of Oncology, First Affiliated Hospital, Guangzhou University of Chinese Medicine, Airport Road, Guangzhou, Guangdong, China
推荐引用方式(GB/T 7714):
Xiaowei Ye,Dongyan Lu,Xinlin Chen,et al.A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain[J].JOURNAL OF PAIN AND SYMPTOM MANAGEMENT.2016,51(6):979-986.doi:10.1016/j.jpainsymman.2015.12.330.
APA:
Xiaowei Ye,Dongyan Lu,Xinlin Chen,Suihui Li,Yao Chen&Li Deng.(2016).A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain.JOURNAL OF PAIN AND SYMPTOM MANAGEMENT,51,(6)
MLA:
Xiaowei Ye,et al."A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Shuangbai San for Treating Primary Liver Cancer Patients With Cancer Pain".JOURNAL OF PAIN AND SYMPTOM MANAGEMENT 51..6(2016):979-986